American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

Bruce E. Hillner, James N. Ingle, Rowan T. Chlebowski, Julie Gralow, Gary C. Yee, Nora A. Janjan, Jane A. Cauley, Brent A. Blumenstein, Kathy S. Albain, Allan Lipton, Susan Brown

Research output: Contribution to journalArticle

831 Citations (Scopus)

Abstract

Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.

Original languageEnglish (US)
Pages (from-to)4042-4057
Number of pages16
JournalJournal of Clinical Oncology
Volume21
Issue number21
DOIs
StatePublished - Nov 1 2003

Fingerprint

Diphosphonates
Breast Neoplasms
Bone and Bones
zoledronic acid
pamidronate
Health
Creatinine
Drug Labeling
Women's Health
Complementary Therapies
Palliative Care
Osteoporosis
Appointments and Schedules
Guidelines
Neoplasm Metastasis
Pain
Food
Therapeutics
Serum
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. / Hillner, Bruce E.; Ingle, James N.; Chlebowski, Rowan T.; Gralow, Julie; Yee, Gary C.; Janjan, Nora A.; Cauley, Jane A.; Blumenstein, Brent A.; Albain, Kathy S.; Lipton, Allan; Brown, Susan.

In: Journal of Clinical Oncology, Vol. 21, No. 21, 01.11.2003, p. 4042-4057.

Research output: Contribution to journalArticle

Hillner, BE, Ingle, JN, Chlebowski, RT, Gralow, J, Yee, GC, Janjan, NA, Cauley, JA, Blumenstein, BA, Albain, KS, Lipton, A & Brown, S 2003, 'American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer', Journal of Clinical Oncology, vol. 21, no. 21, pp. 4042-4057. https://doi.org/10.1200/JCO.2003.08.017
Hillner, Bruce E. ; Ingle, James N. ; Chlebowski, Rowan T. ; Gralow, Julie ; Yee, Gary C. ; Janjan, Nora A. ; Cauley, Jane A. ; Blumenstein, Brent A. ; Albain, Kathy S. ; Lipton, Allan ; Brown, Susan. / American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 21. pp. 4042-4057.
@article{acf3cc1151ca4e8380b4798b31f3fcea,
title = "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer",
abstract = "Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.",
author = "Hillner, {Bruce E.} and Ingle, {James N.} and Chlebowski, {Rowan T.} and Julie Gralow and Yee, {Gary C.} and Janjan, {Nora A.} and Cauley, {Jane A.} and Blumenstein, {Brent A.} and Albain, {Kathy S.} and Allan Lipton and Susan Brown",
year = "2003",
month = "11",
day = "1",
doi = "10.1200/JCO.2003.08.017",
language = "English (US)",
volume = "21",
pages = "4042--4057",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

AU - Hillner, Bruce E.

AU - Ingle, James N.

AU - Chlebowski, Rowan T.

AU - Gralow, Julie

AU - Yee, Gary C.

AU - Janjan, Nora A.

AU - Cauley, Jane A.

AU - Blumenstein, Brent A.

AU - Albain, Kathy S.

AU - Lipton, Allan

AU - Brown, Susan

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.

AB - Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.

UR - http://www.scopus.com/inward/record.url?scp=0642342669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642342669&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.017

DO - 10.1200/JCO.2003.08.017

M3 - Article

C2 - 12963702

AN - SCOPUS:0642342669

VL - 21

SP - 4042

EP - 4057

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -